TABLE 1.
Patient Demographics
| Overall cohort | Surgery ≤ 90 days after biopsy | Surgery > 90 days after biopsy | |
|---|---|---|---|
| No. of patients | 3149 | 2258 | 891 |
| Median age at biopsy in yrs (interquartile range) | 61 (56-65) | 61 (56-65) | 61 (56-65) |
| Median prebiopsy serum PSA level in ng/mL (interquartile range) | 6.3 (4.6-9.6) | 6.6 (4.7-10.0) | 5.9 (4.5-8.6) |
| Biopsy Gleason score | |||
| 6 | 2192 (70%) | 1517 (67%) | 675 (76%) |
| 7 (3 + 4) | 570 (18%) | 425 (19%) | 145 (16%) |
| 7 (4 + 3) | 224 (7%) | 183 (8%) | 41 (5%) |
| 8-10 | 163 (5%) | 133 (6%) | 30 (3%) |
| Clinical classification | |||
| T1a/b | 73 (2%) | 41 (2%) | 32 (4%) |
| T1c | 1295 (41%) | 844 (38%) | 451 (51%) |
| T2a | 759 (24%) | 562 (25%) | 197 (22%) |
| T2b | 313 (10%) | 254 (11%) | 59 (7%) |
| T2c | 607 (19%) | 472 (21%) | 135 (15%) |
| T3 | 81 (3%) | 67 (3%) | 14 (2%) |
| Median nomogram-predicted probability of 5-yr disease progression-free survival (interquartile range) | 84% (71-90%) | 82% (68-89%) | 86% (77-91%) |
| Time to surgery | |||
| < 1 mo | 233 (7%) | ||
| 1-2 mos | 985 (31%) | ||
| 2-3 mos | 1040 (33%) | ||
| 3-4 mos | 496 (16%) | ||
| 4-5 mos | 188 (6%) | ||
| 5-6 mos | 87 (3%) | ||
| 6-9 mos | 100 (3%) | ||
| 9-12 mos | 20 (1%) |
PSA: prostate-specific antigen.